391 related articles for article (PubMed ID: 36578543)
1. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.
Singh DD; Lee HJ; Yadav DK
Front Pharmacol; 2022; 13():1089066. PubMed ID: 36578543
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer.
O'Sullivan CC; Smith KL
Curr Breast Cancer Rep; 2014 Sep; 6(3):169-182. PubMed ID: 25285186
[TBL] [Abstract][Full Text] [Related]
3. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
Le Du F; Diéras V; Curigliano G
Eur J Cancer; 2021 Sep; 154():175-189. PubMed ID: 34280871
[TBL] [Abstract][Full Text] [Related]
4. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
6. Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review.
Chi Y; Shang M; Xu L; Gong H; Tao R; Song L; Zhang B; Yin S; Cong B; Li H
Front Oncol; 2022; 12():811919. PubMed ID: 35251981
[TBL] [Abstract][Full Text] [Related]
7. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.
Schlam I; Swain SM
NPJ Breast Cancer; 2021 May; 7(1):56. PubMed ID: 34016991
[TBL] [Abstract][Full Text] [Related]
9. Emerging Targeted Therapies for HER2-Positive Breast Cancer.
Mercogliano MF; Bruni S; Mauro FL; Schillaci R
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046648
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive clinical evaluation of HER2-TKIs in patients with previously treated HER2-positive metastatic breast cancer.
Ji WJ; Lu X; Wang YG; Chen LW
Anticancer Drugs; 2024 Jul; 35(6):584-596. PubMed ID: 38518088
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends.
Vega Cano KS; Marmolejo Castañeda DH; Escrivá-de-Romaní S; Saura C
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612047
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.
Ferrando-Díez A; Felip E; Pous A; Bergamino Sirven M; Margelí M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884366
[TBL] [Abstract][Full Text] [Related]
13. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
Kunte S; Abraham J; Montero AJ
Cancer; 2020 Oct; 126(19):4278-4288. PubMed ID: 32721042
[TBL] [Abstract][Full Text] [Related]
14. Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.
Aapro M; Cardoso F; Curigliano G; Eniu A; Gligorov J; Harbeck N; Mueller A; Pagani O; Paluch-Shimon S; Senkus E; Thürlimann B; Zaman K
Breast; 2022 Dec; 66():145-156. PubMed ID: 36279803
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors in breast cancer (Review).
Iancu G; Serban D; Badiu CD; Tanasescu C; Tudosie MS; Tudor C; Costea DO; Zgura A; Iancu R; Vasile D
Exp Ther Med; 2022 Feb; 23(2):114. PubMed ID: 34970337
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in novel targeted therapies for HER2-positive breast cancer.
Murphy CG; Morris PG
Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
[TBL] [Abstract][Full Text] [Related]
17. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.
Xuhong JC; Qi XW; Zhang Y; Jiang J
Am J Cancer Res; 2019; 9(10):2103-2119. PubMed ID: 31720077
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy for metastatic HER2-positive breast cancer.
Bredin P; Walshe JM; Denduluri N
Semin Oncol; 2020 Oct; 47(5):259-269. PubMed ID: 32896428
[TBL] [Abstract][Full Text] [Related]
20. HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.
Singla H; Munshi A
Crit Rev Oncog; 2020; 25(3):241-250. PubMed ID: 33463944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
